CN1283253C - 脱氧鸭嘴花碱在制备治疗临床抑郁症的药物中的应用 - Google Patents

脱氧鸭嘴花碱在制备治疗临床抑郁症的药物中的应用 Download PDF

Info

Publication number
CN1283253C
CN1283253C CNB028254031A CN02825403A CN1283253C CN 1283253 C CN1283253 C CN 1283253C CN B028254031 A CNB028254031 A CN B028254031A CN 02825403 A CN02825403 A CN 02825403A CN 1283253 C CN1283253 C CN 1283253C
Authority
CN
China
Prior art keywords
depression
drug
use according
abuse
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028254031A
Other languages
English (en)
Chinese (zh)
Other versions
CN1604781A (zh
Inventor
约阿希姆·莫尔曼
赫尔曼·穆克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HF Arzneimittelforschung GmbH and Co KG
Original Assignee
HF Arzneimittelforschung GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HF Arzneimittelforschung GmbH and Co KG filed Critical HF Arzneimittelforschung GmbH and Co KG
Publication of CN1604781A publication Critical patent/CN1604781A/zh
Application granted granted Critical
Publication of CN1283253C publication Critical patent/CN1283253C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CNB028254031A 2001-12-21 2002-12-14 脱氧鸭嘴花碱在制备治疗临床抑郁症的药物中的应用 Expired - Fee Related CN1283253C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10163667.9 2001-12-21
DE10163667A DE10163667B4 (de) 2001-12-21 2001-12-21 Verwendung von Desoxypeganin zur Behandlung der klinischen Depression

Publications (2)

Publication Number Publication Date
CN1604781A CN1604781A (zh) 2005-04-06
CN1283253C true CN1283253C (zh) 2006-11-08

Family

ID=7710660

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028254031A Expired - Fee Related CN1283253C (zh) 2001-12-21 2002-12-14 脱氧鸭嘴花碱在制备治疗临床抑郁症的药物中的应用

Country Status (29)

Country Link
US (1) US20050009813A1 (enExample)
EP (1) EP1461042B1 (enExample)
JP (1) JP2005513105A (enExample)
KR (1) KR100614504B1 (enExample)
CN (1) CN1283253C (enExample)
AR (1) AR037967A1 (enExample)
AT (1) ATE404203T1 (enExample)
AU (1) AU2002363874B2 (enExample)
BR (1) BR0215306A (enExample)
CA (1) CA2471338C (enExample)
CZ (1) CZ301210B6 (enExample)
DE (2) DE10163667B4 (enExample)
DK (1) DK1461042T3 (enExample)
EA (1) EA006896B1 (enExample)
ES (1) ES2312657T3 (enExample)
HU (1) HUP0402298A3 (enExample)
IL (2) IL162509A0 (enExample)
MX (1) MXPA04006125A (enExample)
MY (1) MY138088A (enExample)
NO (1) NO326446B1 (enExample)
NZ (1) NZ533249A (enExample)
PL (1) PL370315A1 (enExample)
PT (1) PT1461042E (enExample)
SI (1) SI1461042T1 (enExample)
SK (1) SK287152B6 (enExample)
TW (1) TWI241189B (enExample)
UA (1) UA76254C2 (enExample)
WO (1) WO2003053445A1 (enExample)
ZA (1) ZA200404053B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ES2708552T3 (es) * 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
JP5000932B2 (ja) * 2005-06-21 2012-08-15 日東電工株式会社 ニコチン含有経皮吸収製剤
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
CN101433565B (zh) * 2008-11-26 2013-06-05 上海中医药大学 骆驼蓬属种子总生物碱提取物和它们的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit

Also Published As

Publication number Publication date
IL162509A (en) 2010-06-16
EA006896B1 (ru) 2006-04-28
NO326446B1 (no) 2008-12-08
KR100614504B1 (ko) 2006-08-22
MXPA04006125A (es) 2005-05-16
AR037967A1 (es) 2004-12-22
DK1461042T3 (da) 2008-12-01
ZA200404053B (en) 2004-10-12
TWI241189B (en) 2005-10-11
HUP0402298A3 (en) 2011-03-28
WO2003053445A8 (de) 2004-07-01
EP1461042A1 (de) 2004-09-29
KR20040068327A (ko) 2004-07-30
DE10163667B4 (de) 2006-10-26
CN1604781A (zh) 2005-04-06
IL162509A0 (en) 2005-11-20
BR0215306A (pt) 2004-12-21
HUP0402298A2 (hu) 2005-02-28
CA2471338A1 (en) 2003-07-03
CZ2004739A3 (cs) 2004-12-15
CZ301210B6 (cs) 2009-12-09
PT1461042E (pt) 2008-11-03
CA2471338C (en) 2009-02-24
UA76254C2 (en) 2006-07-17
DE50212649D1 (de) 2008-09-25
DE10163667A1 (de) 2003-07-10
HK1066742A1 (zh) 2005-04-01
SK287152B6 (sk) 2010-01-07
EP1461042B1 (de) 2008-08-13
SK2582004A3 (en) 2004-12-01
AU2002363874A1 (en) 2003-07-09
NO20042476L (no) 2004-06-14
ATE404203T1 (de) 2008-08-15
WO2003053445A1 (de) 2003-07-03
AU2002363874B2 (en) 2007-12-13
TW200301124A (en) 2003-07-01
MY138088A (en) 2009-04-30
PL370315A1 (en) 2005-05-16
US20050009813A1 (en) 2005-01-13
ES2312657T3 (es) 2009-03-01
NZ533249A (en) 2007-05-31
EA200400751A1 (ru) 2004-12-30
SI1461042T1 (sl) 2009-02-28
JP2005513105A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
US20020019421A1 (en) Compositions and therapy for substance addiction
JP2009511618A (ja) 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
EA038531B1 (ru) Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
KR102597910B1 (ko) 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
CN111902140A (zh) 用于预防或治疗瘙痒的含有作为活性成分的hdac6抑制剂的药物组合物
CN1283253C (zh) 脱氧鸭嘴花碱在制备治疗临床抑郁症的药物中的应用
MXPA04006124A (es) Cabeza de cilindro.
AU716972B2 (en) Method for treating bipolar disorder
MXPA04006126A (es) Acero para herramientas de arranque de viruta.
CN1300217A (zh) 瑞波西汀与吲哚洛尔的新的药物组合
TW201841630A (zh) 醫藥組合及其用於治療突觸核蛋白病症之用途
CN100540004C (zh) 经鼻给药的吡贝地尔药物组合物
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation
CN1771029A (zh) 用于治疗酒精滥用的活性物质组合物及疗法
CA2338330A1 (en) Use of moclobemide for treating certain phsychiatric and medical disorders
JP2025531623A (ja) タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法
CN119326767A (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
BR112021012491A2 (pt) Combinações antineurodegenerativas de domperidona e uso
CN108159032A (zh) 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法
CN108883089A (zh) 用于治疗偏头痛的制剂
HK1115329A1 (en) Use of (1s, 2r) enantiomer of milnacipran for the preparation of a medicine
HK1079117A1 (zh) 米那普仑的对映体(1s，2r)在药物制备上的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061108

Termination date: 20111214